MBOT microbotmedical.com: Company Value to Revenue

Official company branding of Microbot Medical (MBOT)

The resilience of Microbot Medical Inc. (MBOT) is based on adherence to ESG principles and strict bioethics. The firm's EV/Sales multiple valuation demonstrates market expectations, where the -28785.71 level captures the current state. Updated calibration stands in sterile workshops support this stability. Growth potential relies on the future commercialization of microrobots for minimally invasive neurosurgical procedures.

microbotmedical.com (MBOT): Enterprise Value-to-Revenue Ratio from 11/23/2025 to 11/20/2026

MBOT (Microbot Medical, Inc): analytical breakdowns and indicator data

- current quotes and average value forecast:
Initial company analysis:Microbot Medical Inc.
Manufactured products of Microbot Medical Inc

Investors must evaluate the capitalization stability of Microbot Medical Inc. (MBOT) relative to its actual cash flows. For this endovascular surgery innovator, such analysis is critical due to the high cost of micro-robot development. This enterprise value-to-revenue ratio measures the overall business value, excluding the impact of debt load. An upward trend on this chart signals inflated market expectations, while a decline in the metric indicates that the company's assets are undervalued.

Competitor analysis for Microbot Medical Inc.

ISRG - EV/Sales Multiple|DHR: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple BD (BDX)|Enterprise Value-to-Revenue Ratio STERIS plc|Company Value to Revenue Ratio WST (West Pharmaceutical Services)|Company Value to Revenue BAX (Baxter Corp)|Masimo - Company Value to Revenue Ratio|Stevanato Group S.p.A. - Company Value to Revenue|Total Company Value-to-Revenue Ratio Teleflex Inc (TFX)|MMSI - Enterprise Value-to-Revenue Ratio|Total Company Value-to-Revenue Ratio Envista Holdings Corp NVST|ICUI: EV/Sales Multiple|Company Value to Revenue Ratio XRAY|LMAT (LeMaitre Corp) - EV/Sales Multiple|ATRC (AtriCure Inc) - Enterprise Value-to-Revenue Coefficient|EV/Sales Multiple STAA|NAGE (ChromaDex Corp) - Business Value to Revenue|ZimVie Inc. - Company Value to Revenue|Total Company Value-to-Revenue Ratio angiodynamics.com (ANGO)|CERS - Enterprise Value-to-Revenue Ratio|TKNO - EV/Sales Multiple|Monogram Technologies Inc (MGRM) - Enterprise Value-to-Revenue Ratio|STSS - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio InfuSystem Holdings, Inc.|Enterprise Value-to-Revenue Multiple Utah Medical Products UTMD|EV/Sales Multiple KRMD|Total Company Value-to-Revenue Ratio Nyxoah, S.A.|EV/Sales Multiple PDEX (Pro-Dex Inc.)|Enterprise Value-to-Revenue Coefficient ZTEK (Zentek Limited)|elutia.com - EV/Sales Multiple|Business Value to Revenue MLSS (milestonescientific.com)|NXGL (NEXGEL Inc.) - Company Value to Revenue|Retractable Technologies - Business Value to Revenue|Enterprise Value-to-Revenue Ratio harvardbioscience.com|Femasys Corp (FEMY) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple MHUA|Predictive Oncology Inc. - Company Value to Revenue Ratio|EV/Sales Multiple CJMB (Callan JMB Inc)|EV/Sales Multiple Atrion Corp ATRI|NeuroMetrix Corporation - EV/Sales Multiple